TY - JOUR
T1 - A Comprehensive Practice Guideline for Magnetic Resonance Imaging Compatibility in Implanted Neuromodulation Devices
AU - Sayed, Dawood
AU - Chakravarthy, Krishnan
AU - Amirdelfan, Kasra
AU - Kalia, Hemant
AU - Meacham, Kathleen
AU - Shirvalkar, Prasad
AU - Falowski, Steven
AU - Petersen, Erika
AU - Hagedorn, Jonathan M.
AU - Pope, Jason
AU - Leever, John
AU - Deer, Timothy
N1 - Funding Information:
Source(s) of financial support: This project was created and completed by the American Society of Pain and Neuroscience (ASPN) with no outside corporate funding. Conflict of Interest:
Funding Information:
The authors thank Allison Foster, PhD, an independent medical writer, for her intellectual contribution to the editing of the manuscript. All authors made a substantial contribution to the manuscript's design and content, and approved its final version. The ASPN MRI Compatibility Working Group is comprised of Amitabh Gulati, MD (Associate Attending and Director of Chronic Pain, Memorial Sloan Kettering Cancer Center, NY, NY, USA); Corey W. Hunter, MD (Executive Director, Ainsworth Institute of Pain Management, New York City, NY, USA; Assistant Clinical Professor Department of Physical Medicine & Rehabilitation, Icahn School of Medicine at Mount Sinai Hospital, New York City, NY, USA); Mark Malinowski, DO (Adena Spine Center, Adena Health System, Chillicothe, OH, USA; Ohio University Heritage College of Osteopathic Medicine, Athens, OH, USA); Ajay Antony, MD (The Orthopedic Institute, Gainesville, FL, USA); Jay M. Shah, MD (SamWell Institute for Pain Management, Colonia, NJ, USA); Jay Grider, DO, PhD (University of Kentucky, Lexington, KY, USA); Karina Gritsenko, MD (Montefiore Medical Center, Albert Einstein College of Medicine, New York City, NY, USA); Eellan Sivanesan, MD (Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD, USA); John S. Michels, MD (Interventional Spine & Pain, Dallas, TX, USA); Michael Harned, MD (Department of Anesthesiology, Division of Pain Management, University of Kentucky, Lexington, KY, USA); Justin Craig, MD (Department of Anesthesiology, Division of Pain Management, University of Kentucky, Lexington, KY, USA); Neel Mehta, MD (Weill Cornell Medicine, New York City, NY, USA); Rany T. Abdallah, MD, PhD, MBA (University of Vermont Medical Center, Burlington, VT, USA); Sean Li, MD (Premier Pain Centers, Shrewsbury, NJ, USA); Maged Guirguis, MD (System Chair of Interventional Pain Management and Associate Professor of Department of Anesthesiology & Critical Care Medicine, Ochsner Health System and University of Queensland Ochsner Medical School, New Orleans, LA, USA; Clinical Assistant Professor, Louisiana State University School of Medicine, Baton Rouge, LA, USA); Dipan Patel, MD (Garden State Pain Control Center, Clifton, NJ, USA); Rick M. Paicius, MD (Southern California Spine and Sport, Newport Beach, CA, USA); Christopher M. Lam, MD (University of Kansas Medical Center, Kansas City, KS, USA); David Kim, MD, MS (Chronic Pain Medicine Fellow, Department of Anesthesiology, Kansas University Medical Center, Kansas City, KS, USA); Usman Latif, MD, MBA (Assistant Professor and Co-Director, Advanced Analytics and Informatics, The University of Kansas Hospital, Kansas City, KS, USA); Stanley Golovac, MD (Board certified in Anesthesiology and Pain Medicine, Founder of Florida Pain Institute, Melbourne, FL, USA); Navdeep S. Jassal, MD (Founder, Spine & Pain Institute of Florida, Lakeland, FL, USA; Assistant Clinical Professor, Department of Neurology/ Pain, University of South Florida, Tampa, FL, USA Assistant Professor, Department of Physical Medicine and Rehabilitation, University of Central Florida, Orlando, FL, USA); Alexios Carayannopoulos, DO, MPH (Chief of the Department of Physical Medicine and Rehabilitation, Rhode Island Hospital, Newport Hospital, Lifespan Physician Group, Providence, RI, USA; Medical Director of the Comprehensive Spine Center at Rhode Island Hospital, Newport Hospital, Providence, RI, USA; Associate Professor of Neurosurgery at the Warren Alpert Medical School of Brown University, Providence, RI, USA); Louis J. Raso, MD (Jupiter Interventional Pain Management, Jupiter, FL, USA); Marshall Bedder, MD FRCPC DABA, DABAM, FASAM (Clinical Associate Professor of Psychiatry and Health Behavior, Medical College of Georgia - Augusta University, Augusta, GA, USA; Attending Physician, Augusta Pain Center, Augusta, GA, USA); Youssef Josephson, DO, FAAPMR (Assistant Professor of Physical Medicine & Rehabilitation, Pain Management, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA. Faculty, Thomas Jefferson University Hospital, Philadelphia, PA, USA; Administrative Director of The Pain Management Center, Voorhees, NJ, USA); Philip Kim, MD (Center for Interventional Pain & Spine, Philadelphia, PA, USA); Adem Aktas, DO (Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA); Kiran V. Patel, MD (Interventional Pain Medicine, The Spine & Pain Institute of New York, New York City, NY, USA); Heather Pinckard-Dover, MD (Associate Professor, Department of Neurosurgery, University of Arkansas for Medical Sciences, Little Rock, AR, USA); Tess L. Veuthey, PhD (Graduate School of Neuroscience, University of California San Francisco, San Francisco, CA, USA); Jonathan Schor, PhD (Graduate School of Neuroscience, University of California San Francisco, San Francisco, CA, USA); Ankit Khambhati, PhD (Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA); and Gregory Chin, BS (Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA).
Publisher Copyright:
© 2020 International Neuromodulation Society
PY - 2020/10
Y1 - 2020/10
N2 - Objectives: The evolution of neuromodulation devices in order to enter magnetic resonance imaging (MRI) scanners has been one of understanding limitations, engineering modifications, and the development of a consensus within the community in which the FDA could safely administer labeling for the devices. In the initial decades of neuromodulation, it has been contraindicated for MRI use with implanted devices. In this review, we take a comprehensive approach to address all the major products currently on the market in order to provide physicians with the ability to determine when an MRI can be performed for each type of device implant. Materials and Methods: We have prepared a narrative review of MRI guidelines for currently marketed implanted neuromodulation devices including spinal cord stimulators, intrathecal drug delivery systems, peripheral nerve stimulators, deep brain stimulators, vagal nerve stimulators, and sacral nerve stimulators. Data sources included relevant literature identified through searches of PubMed, MEDLINE/OVID, SCOPUS, and manual searches of the bibliographies of known primary and review articles, as well as manufacturer-provided information. Results: Guidelines and recommendations for each device and their respective guidelines for use in and around MR environments are presented. Conclusions: This is the first comprehensive guideline with regards to various devices in the market and MRI compatibility from the American Society of Pain and Neuroscience.
AB - Objectives: The evolution of neuromodulation devices in order to enter magnetic resonance imaging (MRI) scanners has been one of understanding limitations, engineering modifications, and the development of a consensus within the community in which the FDA could safely administer labeling for the devices. In the initial decades of neuromodulation, it has been contraindicated for MRI use with implanted devices. In this review, we take a comprehensive approach to address all the major products currently on the market in order to provide physicians with the ability to determine when an MRI can be performed for each type of device implant. Materials and Methods: We have prepared a narrative review of MRI guidelines for currently marketed implanted neuromodulation devices including spinal cord stimulators, intrathecal drug delivery systems, peripheral nerve stimulators, deep brain stimulators, vagal nerve stimulators, and sacral nerve stimulators. Data sources included relevant literature identified through searches of PubMed, MEDLINE/OVID, SCOPUS, and manual searches of the bibliographies of known primary and review articles, as well as manufacturer-provided information. Results: Guidelines and recommendations for each device and their respective guidelines for use in and around MR environments are presented. Conclusions: This is the first comprehensive guideline with regards to various devices in the market and MRI compatibility from the American Society of Pain and Neuroscience.
KW - Deep brain stimulation
KW - MRI
KW - dorsal column stimulation
KW - dorsal root ganglion stimulation
KW - guideline
KW - intrathecal pump
KW - medical devices
KW - spinal cord stimulation
UR - http://www.scopus.com/inward/record.url?scp=85089506746&partnerID=8YFLogxK
U2 - 10.1111/ner.13233
DO - 10.1111/ner.13233
M3 - Review article
C2 - 32809275
AN - SCOPUS:85089506746
SN - 1094-7159
VL - 23
SP - 893
EP - 911
JO - Neuromodulation
JF - Neuromodulation
IS - 7
ER -